Afimoxifene

Drug Profile

Afimoxifene

Alternative Names: 4-Hydroxytamoxifen; 4-Hydroxytamoxifen (afimoxifene) gel; 4-Hydroxytamoxifen gel; 4-OH tamoxifen; 4-OHT; TamoGel

Latest Information Update: 02 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Besins International
  • Developer Atossa Genetics; Besins Healthcare; BHR Pharma
  • Class Antineoplastics; Hydroxytestosterones; Non-opioid analgesics
  • Mechanism of Action Estrogen receptor antagonists; Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hyperplasia
  • Phase II Breast cancer
  • No development reported Breast pain; Gynaecomastia
  • Discontinued Keloids

Most Recent Events

  • 21 Aug 2017 Phase-III clinical trials in Hyperplasia in USA (Topical) (NCT03199963)
  • 03 Jul 2017 BHR Pharma plans a phase III trial for Hyperplasia (NCT03199963)
  • 31 May 2017 National Cancer Institute initiates enrolment in a phase IIb trial for Breast cancer in USA (Topical) (NCT02993159)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top